Q-omics provides the consensus-scored PPP1R42 profile across patient tissues and cancer cell-line models. PPP1R42 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPP1R42 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, PPP1R42 RNA expression shows 16,014 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where PPP1R42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R42 survival associations across molecular data types. PPP1R42 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R42 RNA expression–survival associations across cancer types. High PPP1R42 expression shows unfavorable associations in LIHC, READ and LGG, but favorable associations in ACC, BRCA and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for PPP1R42 RNA expression.
This table summarizes PPP1R42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPP1R42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R42 shows lower tumor expression in KICH, THCA, KIRC, LUSC and LUAD and higher tumor expression in LIHC. The KICH box plot shows higher PPP1R42 RNA expression in normal versus tumor tissue (log2 FC = −1.182, t-test p < 0.001).
This table shows molecular features associated with PPP1R42 in patient tissues and cancer cell lines. In patient samples, PPP1R42 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
